Stocks › KRYS
Krystal Biotech, Inc.
KRYS·Nasdaq·
United States·USD
United States·USD$326.81
-8.04 (-2.40%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
KRYS
Krystal Biotech, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
KRYSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of KRYS by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
KRYSKrystal Biotech, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Whale Activity
Position changes in KRYS reported for 2026-06-30 by 14 tracked institutional filers
- Increased5
- New1
- Held0
- Decreased1
- Closed2
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 4.2M | $1.55B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $585.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $461.1M | increased |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 570.2K | $211.9M | — |
| Biondo Investment Advisors, LLC | 70.9K | $26.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | 59.7K | $22.2M | increased |
| Bridgewater Associates, LP | 54.5K | $20.3M | increased |
| Tetragon Partners GP Ltd | 19.7K | $7.3M | — |
| CIM, LLC | 15.7K | $5.8M | — |
| Evolutionary Tree Capital Management, LLC | 8,301 | $3.1M | — |
| TWO SIGMA INVESTMENTS, LP | 6,084 | $2.3M | new |
| CITADEL ADVISORS LLC | 2,725 | $1.0M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by KRYS insiders, by quarter · Form 4
Recent Insider Transactions
698 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Krishnan SumaPresident, R&D · Director | Sale | −826 | $365.41 | $302K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −565 | $363.34 | $205K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −520 | $354.54 | $184K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −399 | $366.56 | $146K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −3,962 | $357.57 | $1.4M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −3,392 | $359.39 | $1.2M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −3,267 | $356.37 | $1.2M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −3,180 | $358.42 | $1.1M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −2,320 | $360.47 | $836K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −2,006 | $355.57 | $713K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −1,992 | $362.65 | $722K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −1,329 | $364.48 | $484K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan SumaPresident, R&D · Director | Sale | −1,242 | $361.61 | $449K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −847 | $365.42 | $310K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −573 | $363.34 | $208K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −520 | $354.54 | $184K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −405 | $366.56 | $148K | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −3,981 | $357.57 | $1.4M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −3,357 | $359.39 | $1.2M | Sep 4, 2026 | Form 4 ↗ |
| Krishnan Krish SPresident and CEO · Director | Sale | −3,297 | $356.37 | $1.2M | Sep 4, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding KRYS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 1.6M | $587.4M | 0.53% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 1.8M | $557.1M | 10.58% | May 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 889.5K | $330.6M | 0.01% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 752.2K | $279.6M | 0.30% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 670.9K | $249.3M | 0.30% | Jun 30, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 788.5K | $243.7M | 0.25% | May 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 642.5K | $238.8M | 0.13% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 370.5K | $137.7M | 0.29% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund Manager Directed Portfolios | 329.8K | $122.6M | 1.84% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 318.7K | $118.5M | 1.10% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list KRYS's shares (CUSIP 501147102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Krystal Biotech, Inc. as client
No lobbying filings found naming Krystal Biotech, Inc. as the client.
Government Contracts
Federal awards to Krystal Biotech, Inc. · USAspending
No federal contract awards found for Krystal Biotech, Inc..
U.S. Patents
Recent USPTO applications naming Krystal Biotech, Inc.
No USPTO patent applications found for Krystal Biotech, Inc..
Annual Financials
From KRYS's 10-K filings · XBRL
No annual XBRL figures on record for KRYS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in KRYS's price history.
About Krystal Biotech, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersPITTSBURGH, PA
SEC CIK0001711279 ↗